Back to research

Research paper

Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse

Prospective web-based multi-center study of 85 MS patients receiving high-dose IVMP, with self-report at baseline, day 2 of treatment, day 1 post-treatment, and 1 week post-treatment. Median 4 AEs per pulse. Most frequent: change in taste (61%), facial flushing (61%), feeling sick / stomach pain (53%), sleep disturbance (44%), appetite change (37%), agitation (36%), behavioral changes (36%). Sleep disturbance, agitation, anger/bad temper, depression, behavioral change classified as CNS-related and persisted at 1 week post-treatment.

Indexed context

Morrow SA, et al.

methylprednisoloneintravenous-pulseadverse-effectspatient-reportedsleep-disturbanceagitationbehavioral-changesmultiple-sclerosis

Markdown path

content/research/papers/2016-morrow-ivmp-patient-reported-ae.md

Findings

Prospective web-based multi-center study of 85 MS patients receiving high-dose IVMP, with self-report at baseline, day 2 of treatment, day 1 post-treatment, and 1 week post-treatment. Median 4 AEs per pulse. Most frequent: change in taste (61%), facial flushing (61%), feeling sick / stomach pain (53%), sleep disturbance (44%), appetite change (37%), agitation (36%), behavioral changes (36%). Sleep disturbance, agitation, anger/bad temper, depression, behavioral change classified as CNS-related and persisted at 1 week post-treatment.

Why it may matter for Levi

Establishes that CNS-related effects (sleep disturbance, agitation, behavioral change) are extremely common after IVMP — on the order of 30–45% in self-report — and persist at least 1 week post-pulse. Sleep disturbance is one of the most common AEs and is a strong independent driver of irritability and aggression in young children, so even if direct mood effects fade, residual sleep disruption could be propagating into Levi's current behavior. Maximum follow-up is 1 week, so the study cannot directly speak to the 3-week-later window; Lorefice 2018 fills that gap.

Paper text

Morrow et al. (2016) — Patient-reported adverse effects of high-dose IV methylprednisolone

Source

Why this paper is in the corpus

This study quantifies the frequency and persistence of CNS-related adverse effects during and shortly after a high-dose IVMP pulse using patient self-report, with measurements at baseline, day 2 of treatment, day 1 post-treatment, and 1 week post-treatment.

Key findings

  • 85 MS patients self-reported a median of 4 adverse effects per pulse.
  • Most frequent AEs: change in taste (61%), facial flushing (61%), feeling sick / stomach pain (53%), sleep disturbance (44%), appetite change (37%), agitation (36%), behavioral changes (36%).
  • Sleep disturbance, agitation, anger/bad temper, depression, over-optimism, and behavioral change were classified as CNS-related AEs.
  • Multiple CNS AEs were still present at the 1-week-post-treatment timepoint (i.e., not all resolved within days of completing the pulse).

Limitations relevant to Levi

  • Adult MS cohort, not pediatric.
  • Maximum follow-up was 1 week post-pulse — the study cannot speak to whether AEs persist or rebound at 3–6 weeks (which is what Levi's family is observing now). The Lorefice 2018 study fills part of that gap.
  • Self-report; subclinical irritability not requiring patient acknowledgement is not captured.

Levi-relevant takeaways

  • Establishes that CNS-related effects (sleep disturbance, agitation, behavioral change) are extremely common after IVMP — on the order of 30–45% in self-report — and that they persist at least a week after the pulse, which is the longest interval rigorously studied in this paper.
  • Sleep disturbance specifically is one of the most common AEs and is a strong independent driver of irritability and aggression in young children, so even if direct mood effects fade, residual sleep disruption could be propagating into behavior.